CAF regimen: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
{{SK}} CAF; CAFFI; CAF Regimen; CDF; CTX/DOX/5-FU; Cyclophosphamide-Adriamycin-Fluorouracil Regimen; Cyclophosphamide/Doxorubicin/Fluorouracil; FAC | {{SK}} CAF; CAFFI; CAF Regimen; CDF; CTX/DOX/5-FU; Cyclophosphamide-Adriamycin-Fluorouracil Regimen; Cyclophosphamide/Doxorubicin/Fluorouracil; FAC | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a chemotherapy regimen consisting of [[cyclophosphamide]], [[doxorubicin|doxorubicin hdrochloride (Adriamycin)]], and [[fluorouracil]], which may be used in the adjuvant setting for the treatment of nonmetastatic breast cancer or alone for the treatment of metastatic breast cancer.<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | {{PAGENAME}} refers to a chemotherapy regimen consisting of [[cyclophosphamide]], [[doxorubicin|doxorubicin hdrochloride (Adriamycin)]], and [[fluorouracil]], which may be used in the adjuvant setting for the treatment of [[breast cancer|nonmetastatic breast cancer]] or alone for the treatment of [[breast cancer|metastatic breast cancer]].<ref>{{Cite web | title = NCI Thesaurus | accessdate = | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C63452 }}</ref><ref>{{Cite web | title = R-CHOP - National Cancer Institute | accessdate = | url = http://www.cancer.gov/cancertopics/druginfo/R-CHOP }}</ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|C|Cyclophosphamide}} | |||
{{chemo|A|Doxorubicin (Adriamycin)}} | |||
{{chemo|F|Fluorouracil}} | |||
==Indications== | ==Indications== |
Latest revision as of 14:26, 11 March 2015
WikiDoc Resources for CAF regimen |
Articles |
---|
Most recent articles on CAF regimen Most cited articles on CAF regimen |
Media |
Powerpoint slides on CAF regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on CAF regimen at Clinical Trials.gov Clinical Trials on CAF regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on CAF regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on CAF regimen Discussion groups on CAF regimen Patient Handouts on CAF regimen Directions to Hospitals Treating CAF regimen Risk calculators and risk factors for CAF regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for CAF regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: CAF; CAFFI; CAF Regimen; CDF; CTX/DOX/5-FU; Cyclophosphamide-Adriamycin-Fluorouracil Regimen; Cyclophosphamide/Doxorubicin/Fluorouracil; FAC
Overview
CAF regimen refers to a chemotherapy regimen consisting of cyclophosphamide, doxorubicin hdrochloride (Adriamycin), and fluorouracil, which may be used in the adjuvant setting for the treatment of nonmetastatic breast cancer or alone for the treatment of metastatic breast cancer.[1][2]
Regimen
CCyclophosphamide
ADoxorubicin (Adriamycin)
FFluorouracil
Indications
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Khaloozadeh H, Yazdanbakhsh P, Homaei-shandiz F (2008). "The optimal dose of CAF regimen in adjuvant chemotherapy for breast cancer patients at stage IIB". Math Biosci. 213 (2): 151–8. doi:10.1016/j.mbs.2008.04.003. PMID 18533195.